[Beta-blocker prescription and chronic obstructive pulmonary disease].
The beta-blocker (BB) prescription remains insufficient despite guidelines, especially, for chronic heart failure. Patients suffering chronic obstructive pulmonary disease (COPD) are particularly less treated by BB. The level of evidence for BB prescription is however especially high and as we will focus on, the level of evidence for the safety of BB in the COPD context is convincing enough. We, thus, propose to review the existing literature in regard to this prescription of BB in the chronic heart failure, in the coronary artery disease and for high blood pressure in COPD patients. We then propose our approach to improve the level of prescription of BB in COPD patient really justifying this prescription in cardiology.
Ollivier
R
R
Département de cardiologie, hôpital Pontchaillou, CHU, 2, rue Henri-Le-Guillouxn 35033 Rennes cedex 09, France.
Donal
E
E
Delaval
P
P
Daubert
J-C
JC
Mabo
P
P
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002908:Chronic Disease; D003324:Coronary Artery Disease / Q000150:complications* / Q000188:drug therapy*; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications*
D000319:Adrenergic beta-Antagonists